Thrombin generation as marker to estimate thrombosis risk in patients with abnormal test results in lupus anticoagulant routine diagnostics

被引：8

作者：

Boeer K. ^{[1
]}

Cuznetov L. ^{[1
]}

Loesche W. ^{[2
]}

机构：

[1] Institut für Klinische Chemie und Laboratoriumsdiagnostik, Jena University Hospital - Friedrich Schiller University Jena, 07747 Jena

[2] Center for Sepsis Control and Care, Jena University Hospital - Friedrich Schiller University Jena, Jena

来源：

Thrombosis Journal | / 11卷 / 1期

关键词：

Lupus anticoagulant; Thrombin generation; Thrombosis risk;

D O I：

10.1186/1477-9560-11-24

中图分类号：

学科分类号：

摘要：

Background: Lupus anticoagulant (LA) is known to inhibit thrombin generation although patients have an increased risk to develop thrombosis. We tried to determine whether thrombin generation is altered in plasma samples of patients with abnormal test results in LA routine diagnostics and whether its measurement may improve the risk assessment of thrombosis.Methods: Samples from 63 patients (39 with abnormal test results; 24 controls) were included in the study. Measurement of diluted Russel's viper venom time (dRVVT) was part of the initial guideline conform diagnostic procedure for detection of LA. In addition, measurement of anticardiolipin-IgM, -IgG and β2-glycoprotein-I-IgM, -IgG were performed. Thrombin generation was measured using two different phospholipid concentrations in the starting reagent.Results: Analyzing all samples by logistic regression, thrombin generation after induction with high phospholipid concentrations was the best predictor of thrombosis. After preselection of samples with alterations in dRVVT, specificity of selected thrombin generation derived parameters for the detection of previous thrombosis increased in this subgroup.Conclusions: In patients with phospholipid-dependent prolongation of dRVVT, thrombin generation is variably inhibited and the degree of inhibition corresponds to the occurrence of previous thrombosis. Measuring thrombin generation in patients with phospholipid-dependent dRVVT prolongation may improve risk assessment of thrombosis. © 2013 Boeer et al.; licensee BioMed Central Ltd.

引用

共 28 条

[1]

Swadzba J., Iwaniec T., Pulka M., De Laat B., De Groot P.G., Musial J., Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines, J Thromb Haemost, 9, pp. 1776-1783, (2011)

[2]

Pengo V., Tripodi A., Reber G., Rand J.H., Ortel T.L., Galli M., De Groot P.G., Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, J Thromb Haemost, 7, pp. 1737-1740, (2009)

[3]

Devreese K., Peerlinck K., Hoylaerts M.F., Diagnostic test combinations associated with thrombosis in lupus anticoagulant positive patients, Thromb Haemost, 105, pp. 736-738, (2011)

[4]

Galli M., Luciani D., Bertolini G., Barbui T., Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature, Blood, 101, pp. 1827-1832, (2003)

[5]

Galli M., Antiphospholipid antibodies and thrombosis: do test patterns identify the patients' risk?, Thromb Res, 114, pp. 597-601, (2004)

[6]

Ruiz-Irastorza G., Cuadrado M.J., Ruiz-Arruza I., Brey R., Crowther M., Derksen R., Erkan D., Krilis S., Machin S., Pengo V., Et al., Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies, Lupus, 20, pp. 206-218, (2011)

[7]

Ruiz-Irastorza G., Hunt B.J., Khamashta M.A., A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies, Arthritis Rheum, 57, pp. 1487-1495, (2007)

[8]

Schulman S., Svenungsson E., Granqvist S., Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group, Am J Med, 104, pp. 332-338, (1998)

[9]

Akimoto T., Kobayashi S., Tamura N., Ohsawa T., Kawano T., Tanaka M., Hashimoto H., Risk factors for recurrent thrombosis: prospective study of a cohort of Japanese systemic lupus erythematosus, Angiology, 56, pp. 601-609, (2005)

[10]

Berntorp E., Salvagno G.L., Standardization and clinical utility of thrombin-generation assays, Semin Thromb Hemost, 34, pp. 670-682, (2008)

← 1 2 3 →